Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 200 Smith St WALTHAM MA 02451-0099 |
Tel: | 1-212-6001902 |
Website: | https://www.deciphera.com |
IR: | See website |
Key People | ||
Steven L. Hoerter President, Chief Executive Officer, Director | Thomas J. Kelly Chief Financial Officer, Executive Vice President, Treasurer | Dashyant Dhanak Executive Vice President, Chief Scientific Officer |
Matthew L. Sherman Executive Vice President, Chief Medical Officer | Kelley Dealhoy Senior Vice President, Chief Business Officer | Daniel C. Martin Senior Vice President, Chief Commercial Officer | Jama Pitman Senior Vice President, Regulatory, Quality, Portfolio Management |
Business Overview |
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy. |
Financial Overview |
For the fiscal year ended 31 December 2023, Deciphera Pharmaceuticals Inc revenues increased 22% to $163.4M. Net loss increased 9% to $194.9M. Revenues reflect U.S. segment increase of 25% to $121.5M, Rest of world segment increase of 40% to $19.6M, Germany segment increase of 25% to $18M. Higher net loss reflects pharmaceutical, biotechnology segment loss increase of 15% to $211M. |
Employees: | 355 as of Jan 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $839.53M as of Dec 31, 2023 |
Annual revenue (TTM): | $163.36M as of Dec 31, 2023 |
EBITDA (TTM): | -$208.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$194.94M as of Dec 31, 2023 |
Free cash flow (TTM): | -$147.48M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 80,800,062 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |